A practical reference on GIP receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
=== Mammals === Monogamous voles (such as prairie voles) have significantly greater density and distribution of vasopressin receptors in their brain when compared to polygamous voles. These differences are located in the ventral forebrain and the dopamine-mediated reward pathway. Peptide arginine vasopressin (AVP), dopamine, and oxytocin act in this region to coordinate rewarding activities such as mating, and regulate selective affiliation. These species-specific differences have shown to correlate with social behaviors, and in monogamous prairie voles are important for facilitation of pair bonding. When compared to montane voles, which are polygamous, monogamous prairie voles appear to have more of these AVP and oxytocin neurotransmitter receptors. It is important that these receptors are in the reward centers of the brain because that could lead to a conditioned partner preference in the prairie vole compared to the montane vole which would explain why the prairie vole forms pair bonds and the montane vole does not. As noted above, different species of voles vary in their sexual behavior, and these differences correlate with expression levels of vasopressin receptors in reward areas of the brain. Scientists were able to change adult male montane voles' behavior to resemble that of monogamous prairie voles in experiments in which vasopressin receptors were introduced into the brain of male montane voles.
=== Conformation === The secondary structure of intact and PEGylated lysozyme can be characterized by circular dichroism (CD) spectroscopy. The CD spectra range from 189 - 260 nm with a pitch of 0.1 nm showed no significant change in the secondary structure of the intact and PEGylated lysozyme.
=== Amélie of Leuchtenberg === Amélie of Leuchtenberg (1812–1873) was Empress of Brazil as the wife of Emperor Pedro I (also King Pedro IV of Portugal). Between February and September 2012, researchers from the University of São Paulo exhumed her remains, along with those of Pedro I and his first wife, Maria Leopoldina. The investigation revealed that Amélie's body had been mummified, with her skin, hair, and internal organs preserved. Forensic examinations at the Hospital das Clínicas identified an incision in the jugular vein, used to inject aromatic substances such as camphor and myrrh during the original embalming. According to forensic archaeologist Valdirene Ambiel, the preservation was aided by the casket's hermetic seal, which prevented the growth of microorganisms. Before reinterment, the body was re-embalmed using methods similar to the original 19th-century process. The remains of Amélie, Pedro I, and Maria Leopoldina are interred within the crypt of the Monument to the Independence of Brazil in São Paulo.
Nickel(I) complexes are uncommon, but one example is the tetrahedral complex NiBr(PPh3)3. Many nickel(I) complexes have Ni–Ni bonding, such as the dark red diamagnetic K4[Ni2(CN)6] prepared by reduction of K2[Ni2(CN)6] with sodium amalgam. This compound is oxidized in water, liberating H2. It is thought that the nickel(I) oxidation state is important to nickel-containing enzymes, such as [NiFe]-hydrogenase, which catalyzes the reversible reduction of protons to H2.
Sources: en.wikipedia.org
The mdx mouse has been at the forefront of CRISPR-Cas9 gene editing research for Duchenne muscular dystrophy. In 2014, the first successful correction of the dystrophin mutation using CRISPR-Cas9 was demonstrated directly in mdx mice, marking a historic milestone in gene editing therapy. In 2018, researchers used AAV-delivered CRISPR-Cas9 to restore dystrophin expression in mdx mice following a single systemic injection, demonstrating the remarkable potential of this approach. These results in mdx mice directly led to the first CRISPR-based clinical trials for DMD in human patients, representing a direct translation from mouse model to human medicine.
== External links == Official website Duncan Sheik at the Internet Broadway Database Duncan Sheik at IMDb Duncan Sheik at Rounder Records Duncan Sheik discography at Discogs Duncan Sheik at International Songwriters Association
The hypothalamus uses dopamine as a prolactostatin to tell the pituitary to inhibit prolactin; it is also created elsewhere in the brain and the adrenal cortex as a neurotransmitter to affect many other systems. The hypothalamus uses RFRP-3 in mammals or GnIH in avian species to inhibit GnRH. The hypothalamus uses follistatin to tell the pituitary to inhibit follicle-stimulating hormone; it also has many other systemic effects. Myocytes use myostatin to tell each other to inhibit myogenesis. Melanocyte-inhibiting factor (melanostatin) inhibits release of other neuropeptides such as alpha-MSH and also has many other functions. There is a neuropeptide called cortistatin and a class of steroidal cortistatins. Examples of releasing and inhibiting hormones for exocrine hormones are gastrin-releasing peptide (GRP) and gastric inhibitory polypeptide (GIP), which regulate gastrin production.
== History and etymology == The technique of smoke-drying jalapeños can be traced back to the early food preservation practices used in Mesoamerica, even before the Aztecs. The name comes from the Nahuatl word chīlpoctli (pronounced [t͡ʃiːlˈpoːkt͡ɬi]), meaning 'smoked chili'.
=== Good gasoline yields === There are three types of crude oil, light, medium and heavy, according to its density. For gasoline blends, composites which are lighter hydrocarbons are used. Molecular weights of these hydrocarbons are lower than heptane. Since most of Nigerian crudes are either light or medium sweet, creating plentiful amount of diesel, they are more costly than sour crudes. Gasoline is produced from processed crude oil and it is highly valued petroleum products. Therefore, to have maximized profit, refiners seek to boost gasoline yields.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.